John K. Pratt

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

Emily J. Faivre, Keith F. McDaniel, Daniel H. Albert et al. · Nature · 2020 · 389 citations

Bd2 Bromodomain, Medicine, Natural Sciences +9

Discovery of <i>N</i>-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor

Keith F. McDaniel, Le Wang, Todd Soltwedel et al. · Journal of Medicinal Chemistry · 2017 · 133 citations · Full text

Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A

David A. DeGoey, John T. Randolph, Dachun Liu et al. · Journal of Medicinal Chemistry · 2014 · 126 citations

Excellent Potency, Medicinal Chemistry, Hcv Ns5a +11

Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro

Hongmei Mo, Liangjun Lu, Ron Pithawalla et al. · Antimicrobial Agents and Chemotherapy · 2005 · 120 citations · Full text

Viral Replication, Hepatitis C Virus, Viral Hepatitis +12

Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies

Mai H. Bui, Daniel H. Albert, Leiming Li et al. · Cancer Research · 2017 · 118 citations